Technology

Webinar Date/Time: Wednesday, June 12th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

The meeting is scheduled for May in Switzerland.

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

Webinar Date/Time: Thursday, March 21, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

A Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A with Professor Deborah Ancona, founder of the MIT Leadership Center.

While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.

Investigators harness machine learning to evaluate response to sertraline treatment for major depressive disorder.

Its path and application could model the same road as AI.

The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.

EVERSANA's chief innovation discusses his experience with Apple's new device and how he thinks it might impact the life sciences industry.

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.

Portals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.

Dr. Russo discusses how modern innovations will shape the way hospitals operate in years to come.

Sasser discusses how AI is directly helping with problems specific to precision and personalized medicine research.

Webinar Date/Time: Wednesday, March 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Embracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent way of life.

Offerings include treatment plans for a considerable number of illnesses and conditions, company says.

Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?

As the technology becomes more ingrained within the Pharma industry’s processes, experts believe that regulation covering the use of AI is coming.

Study highlights how AI can identify trends and connections that can predict how new patients might respond to therapies.

The device can produce AI-assisted readings.

Each program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.

Why empowering both parties with the tools and data they need to make clinical decisions should be a top priority in the AI renaissance—to bolster patient care and improve health outcomes.

Ginkgo Bioworks announces projected total revenue of $250–$260 million for 2023 for large scale data generation and artificial intelligence for biopharma R&D.